Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate ... Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.

Since 2020, Pfizer has made significant investments in acquisitions, including Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5.4 billion ...

After hours: February 24 at 5:57:57 p.m. EST ...